Immunai has entered a partnership with the Parker Institute for Cancer Immunotherapy to generate an extensive single-cell gene expression dataset from a cancer patient cohort receiving immune checkpoint inhibitors. The dataset will support training of Immunai’s AI platform modeling the human immune system, potentially improving drug discovery and immunotherapy strategies. This collaboration reflects a growing trend where companies leverage high-resolution single-cell data to bolster computational models and precision medicine efforts, facilitating better understanding of immune dynamics in cancer.